with square-planar PtII drugs, PtIV-based anticancer prodrugs are relatively inert under physiological conditions and can be activated after entering cells. The two axial ligands in PtIV complexes provide an opportunity to further functionalize these prodrugs. In recent years, much effort has been devoted to developing new PtIV-based anticancer prodrugs with higher cytotoxicity but fewer side effects.